In a report released today, Tara Bancroft from TD Cowen maintained a Buy rating on Mersana Therapeutics (MRSN – Research Report). The company’s shares opened today at $4.04.
According to TipRanks, Bancroft is a 5-star analyst with an average return of 59.3% and a 75.00% success rate. Bancroft covers the Healthcare sector, focusing on stocks such as Fate Therapeutics, Xencor, and Lantheus.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Mersana Therapeutics with a $3.00 average price target.
See Insiders’ Hot Stocks on TipRanks >>
Based on Mersana Therapeutics’ latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $7.7 million and a GAAP net loss of $41.7 million. In comparison, last year the company earned a revenue of $5.57 million and had a GAAP net loss of $59.8 million
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Mersana Therapeutics (MRSN) Company Description:
Mersana Therapeutics, Inc. engages in the development and manufacture of antibody drug conjugates to improve patient outcomes in multiple oncology indications. Its lead product candidates are XMT-1522, which focuses on breast cancer and non-small cell lung cancer (NSCLC); and XMT-1536, which targets ovarian cancer and NSCLC. The company was founded by Mikhail Papisov in 2001 and is headquartered in Cambridge, MA.
Read More on MRSN:
- Mersana Therapeutics Shares Corporate Presentation Update
- Mersana Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2023 Financial Results
- Mersana Therapeutics to Present at Upcoming Investor Conferences
- Mersana Therapeutics (MRSN) Q4 Earnings Cheat Sheet
- Mersana Therapeutics to Host Fourth Quarter and Year End 2023 Conference Call on February 28, 2024
